CORVITIN® – the only quercetin injectable (senolytic therapy, cardioprotection, fat metabolism) Covid defence

80.00$

CORVITIN® – a solution to reap the benefits of natural quercetin cardioprotector, senolytic

the only injectable quercetin product in the world
Box of 5 vials of 500 mg 

Available on backorder

Description

CORVITIN® – a solution to reap the benefits of natural quercetin

the only injectable quercetin product in the world
Box of 5 vials of 500 mg 

Literature:

Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19)

A role for quercetin in coronavirus disease 2019 (COVID-19)

The effect of quercetin on the prevention or treatment of COVID-19 and other respiratory tract infections in humans: A rapid review

Aqueous injection of quercetin: An approach for confirmation of its direct in vivo cardiovascular effects

Active ingredients:

Quercetin complex with polyvinyl pyrrolidone 500 mg

CORVITIN is a bioflavonoid, capillary stabilizer and antioxidant agent in metabolic processes.

Quercetin exhibits the properties of a modulator of the activity of various enzymes involved in the degradation of phospholipids (phospholipases, phosphogenases, COX), which affect free radical processes and are responsible for the biosynthesis of nitric oxide, proteinases, and others. The inhibitory effect of quercetin on membranotropic enzymes and first of all, 5-lipoxygenase affects the inhibition of the synthesis of leukotrienes LTC 4 and LTB 4 . Along with this, quercetin dose-dependently increases the level of nitric oxide in endothelial cells, which explains its cardioprotective effect in ischemic and reperfusion lesions of the myocardium. Corvitin also exhibits antioxidant and immunomodulating properties, reduces the production of cytotoxic superoxidanion, normalizes the activation of the subpopulation composition of lymphocytes and reduces their activation level. By inhibiting the production of anti-inflammatory cytokines of interleukins (IL) -1β and -8, it helps to reduce the volume of necrotic myocardium and enhance reparative processes.

The drug restores regional blood circulation and microcirculation without noticeable changes in vascular tone, increasing the reactivity of microvessels.

Corvitin normalizes cerebral hemodynamics in ischemic lesions, reduces the coefficient of asymmetry of cerebral blood flow in ischemic stroke.

Indications

  • used as a cardioprotector in combination therapy of acute coronary circulation failure and myocardium infarction;
  • and in the treatment and prevention of reperfusion syndrome in surgery in patients with obliterating atherosclerosis of the abdominal aorta and peripheral arteries.
  • recent research found quercetin to be a highly potent natural senolytic
  • complex therapy for acute violation of coronary circulation and myocardial infarction;
  • complex therapy for decompensation of chronic heart failure;
  • complex therapy for acute ischemic cerebrovascular accident (ischemic stroke, transient ischemic attack) and chronic ischemic diseases of the brain;
  • treatment and prevention of reperfusion syndrome in the surgical treatment of patients with obliterating atherosclerosis of the abdominal aorta and peripheral arteries

Preparation of solution

The solution is prepared in two stages:

Stage 1 – for the initial dilution of the drug, 0.9% sodium chloride solution in the amount of 15 ml is injected with a syringe into the vial with Corvitin, shake the vial until the lyophilized powder is completely dissolved.

2nd stage – transfer the resulting solution to a container with 0.9% sodium chloride solution, the total volume of the finished solution is 50-100 ml, depending on the indications.

If it is necessary to introduce 1 g of Corvitin, the initially diluted preparation of two vials should be transferred to a container with 0.9% sodium chloride solution; the total volume of the prepared solution is 50-100 ml.

Do not mix with other solutions and preparations! Do not use syringes and IV systems that were previously used for other drugs. Corvitin should be diluted immediately before administration! It is not recommended to use a solvent in a volume of more than 100 ml, since with an increase in the volume of solvent, the potential risk of decreasing the stability of the prepared solution increases.

Dosage and pharmaceutical form:

lyophilizate for injection 0.5 g in vials, 5 vials in cassette, 1 cassette in case.

The health benefits or quercetin are incredible – it has proven effective in quite many different health issue.

Please browse throughs some of the selected scientific articles:

Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease

Increased renal cellular senescence in murine high-fat diet: effect of the senolytic drug quercetin

The Cardio- and Neuroprotective Effects of Corvitin and 2-Oxoglutarate in Rats with Pituitrin-Isoproterenol-Induced Myocardial Damage

Effects of flavonol quercetin on activity of lipid peroxide oxidation in experimental bacterial-immune periodontitis

Corvitin Efficiency in Primary Glaucoma

Antiatherogenic effect of quercetin is mediated by proteasome inhibition in the aorta and circulating leukocytes

Combination therapy with Corvitin and Axotilin in the treatment of patients with ischemic stroke

Role of Corvitin in the prevention of reperfusion syndrome

Reperfusion syndrome (MS) is a syndrome resulting from the resumption of blood flow (ie reperfusion) in the ischemic part of the organ: myocardium – in acute infarction, coronary insufficiency; brain – in acute stroke, etc. MS in myocardial infarction is clinically manifested by a significant increase in the intensity of damage to the heart muscle immediately after the resumption of coronary circulation. As a result, the patient’s condition deteriorates sharply. The minimum duration of ischemia after which severe MS occurs is 40 minutes.
In the mechanism of MS development, the following is of primary importance:

  • reactive hyperemia followed by a drop in blood flow below the baseline (“no-reflow” phenomenon), the development of endothelial dysfunction. The severity of these changes depends on the duration of the previous ischemia;
  • intensification of the processes of lipid peroxidation (LPO) of cell membranes and intracellular structures (“oxygen paradox”);
  • excessive accumulation of ionized calcium in cells, which activates calcium-dependent phospholipases, which leads to damage to cell membranes;
  • all of the above aggravates the energy deficit of cells. The mechanisms of apoptosis are activated, and, according to some authors, even in areas that were not subjected to ischemia (Golubev A.M. et al., 2006).

In general, it can be said that MS is not an unforeseen complication, but rather an integral condition after the restoration of blood flow in the ischemic area. In comparison with ischemia of the same duration, MS is accompanied by more pronounced intensification of lipid peroxidation of cell and subcellular membranes, accumulation of calcium and sodium ions in cells, damage to membranes and enzyme systems, and the prevalence of cell death by apoptosis rather than necrosis.
Based on the foregoing, it is advisable to carry out MS prophylaxis, taking into account that hypoxic processes of varying severity will inevitably occur in ischemic tissue after its blood flow is restored. Pharmaceutical agents that, on the one hand, have angioprotective properties and reduce the manifestations of MS at the microcirculation level, and, on the other hand, increase tissue resistance to hypoxia, are promising in terms of MS prevention. One of these drugs is Korvitin, produced by Borshagovskiy FKhZ (Kiev, Ukraine). The bioflavonoid quercetin, which is part of its composition, exhibits the properties of a modulator of the activity of various enzymes involved in the degradation of phospholipids (phospholipases, phosphogenases, cyclooxygenases),influencing free radical processes and responsible for biosynthesis in cells of nitric oxide, proteinases, etc. The inhibitory effect of quercetin on membranotropic enzymes and, first of all, on 5-lipoxygenase affects the inhibition of the synthesis of leukotrienes LTC4 and LTB4. Along with this, quercetin dose-dependently increases the level of nitric oxide in endothelial cells, which explains its cardioprotective effect in ischemic and reperfusion lesions of the myocardium. Corvitin also exhibits antioxidant and immunomodulatory properties, reduces the production of cytotoxic superoxidanion, normalizes the activation of the subpopulation composition of lymphocytes and reduces the level of their activation. By inhibiting the production of anti-inflammatory cytokines interleukins (IL) -1β and -8, it helps to reduce the volume of necrotic myocardium and enhance reparative processes.proteinases, etc. The inhibitory effect of quercetin on membranotropic enzymes and, first of all, on 5-lipoxygenase affects the inhibition of the synthesis of leukotrienes LTC4 and LTB4. Along with this, quercetin dose-dependently increases the level of nitric oxide in endothelial cells, which explains its cardioprotective effect in ischemic and reperfusion lesions of the myocardium. Corvitin also exhibits antioxidant and immunomodulatory properties, reduces the production of cytotoxic superoxidanion, normalizes the activation of the subpopulation composition of lymphocytes and reduces the level of their activation. By inhibiting the production of anti-inflammatory cytokines interleukins (IL) -1β and -8, it helps to reduce the volume of necrotic myocardium and enhance reparative processes.proteinases, etc. The inhibitory effect of quercetin on membranotropic enzymes and, first of all, on 5-lipoxygenase affects the inhibition of the synthesis of leukotrienes LTC4 and LTB4. Along with this, quercetin dose-dependently increases the level of nitric oxide in endothelial cells, which explains its cardioprotective effect in ischemic and reperfusion lesions of the myocardium. Corvitin also exhibits antioxidant and immunomodulatory properties, reduces the production of cytotoxic superoxidanion, normalizes the activation of the subpopulation composition of lymphocytes and reduces the level of their activation. By inhibiting the production of anti-inflammatory cytokines interleukins (IL) -1β and -8, it helps to reduce the volume of necrotic myocardium and enhance reparative processes.on 5-lipoxygenase affects the inhibition of the synthesis of leukotrienes LTC4 and LTB4. Along with this, quercetin dose-dependently increases the level of nitric oxide in endothelial cells, which explains its cardioprotective effect in ischemic and reperfusion lesions of the myocardium. Corvitin also exhibits antioxidant and immunomodulatory properties, reduces the production of cytotoxic superoxidanion, normalizes the activation of the subpopulation composition of lymphocytes and reduces the level of their activation. By inhibiting the production of anti-inflammatory cytokines interleukins (IL) -1β and -8, it helps to reduce the volume of necrotic myocardium and enhance reparative processes.on 5-lipoxygenase affects the inhibition of the synthesis of leukotrienes LTC4 and LTB4. Along with this, quercetin dose-dependently increases the level of nitric oxide in endothelial cells, which explains its cardioprotective effect in ischemic and reperfusion lesions of the myocardium. Corvitin also exhibits antioxidant and immunomodulatory properties, reduces the production of cytotoxic superoxidanion, normalizes the activation of the subpopulation composition of lymphocytes and reduces the level of their activation. By inhibiting the production of anti-inflammatory cytokines interleukins (IL) -1β and -8, it helps to reduce the volume of necrotic myocardium and enhance reparative processes.which explains its cardioprotective effect in ischemic and reperfusion lesions of the myocardium. Corvitin also exhibits antioxidant and immunomodulatory properties, reduces the production of cytotoxic superoxidanion, normalizes the activation of the subpopulation composition of lymphocytes and reduces the level of their activation. By inhibiting the production of anti-inflammatory cytokines interleukins (IL) -1β and -8, it helps to reduce the volume of necrotic myocardium and enhance reparative processes.which explains its cardioprotective effect in ischemic and reperfusion lesions of the myocardium. Corvitin also exhibits antioxidant and immunomodulatory properties, reduces the production of cytotoxic superoxidanion, normalizes the activation of the subpopulation composition of lymphocytes and reduces the level of their activation. By inhibiting the production of anti-inflammatory cytokines interleukins (IL) -1β and -8, it helps to reduce the volume of necrotic myocardium and enhance reparative processes.helps to reduce the volume of necrotic myocardium and enhance reparative processes.helps to reduce the volume of necrotic myocardium and enhance reparative processes.
The mechanism of the protective action is also associated with the prevention of an increase in the concentration of intracellular calcium in platelets and the activation of aggregation with inhibition of thrombogenesis processes.
The drug restores regional blood circulation and microcirculation without noticeable changes in vascular tone, increasing the reactivity of microvessels.
Corvitin normalizes cerebral hemodynamics in ischemic lesions, reduces the asymmetry coefficient of cerebral blood flow in ischemic stroke.
The purpose of this review is to analyze the results of recent published studies on the use of the domestic drug Corvitin to prevent the development of MS in cardiology. The review also presents data from some foreign studies that studied the possible pharmacochemical effects of quercetin in MS.
When analyzing publications on the role of quercetin in MS prevention, one encounters a lack of unified criteria and clear definitions of MS. Research can be classified into three types.
First, the authors simply compare the data of laboratory and instrumental examinations of the main and control groups, as well as the dynamics of improvement in the condition of patients – thus, exclusively the clinical significance of the drug is assessed. The list of examinations carried out in all works is different and depends on the profile of the patients (surgery, cardiology). In surgical practice, publications on the use of Corvitin for the prevention and treatment of MS in abdominal surgery and transplantation appear most often; interest in it also appears in vascular surgery. T.I. Gaponova et al (2015) used Corvitin in patients with chronic ischemia of the lower extremities before and after reconstructive vascular surgery. The authors proposed the following scheme for using the drug in this category of patients: 0,5 g twice a day one day before the proposed surgery, as well as for 7 days in the postoperative period (0.5 g 2 hours after surgery and then every 12 hours). To verify MS, we used hemodynamic parameters, electrocardiograms (ECG), coagulograms, and general blood test data. Corvitin improved the rheological properties of blood, in particular, reduced the level of hyperfibrinogenemia and decreased leukocytosis.
In cardiac practice, MS often occurs when the coronary artery is recanalized causing acute coronary syndrome (ACS), in particular after the use of thrombolytic therapy or percutaneous transluminal coronary angioplasty. Here Corvitin is used from the first day in addition to standard therapy, relying on its antioxidant and angioprotective properties, while the most successful and frequently encountered is the scheme developed by A.N. Parkhomenko et al: 1st day – 0.5 g in 50 ml of isotonic sodium chloride solution three times with an interval of 2 and 12 hours; 2-3 days – in the same dose twice with an interval of 12 hours, 4-5 days – once in a dose of 0.5 g. To assess the effectiveness of the drug in terms of MS prevention in patients with ACS with ST segment elevation A.L. Alyavi and M.L.Kenzhaev (2009) evaluated the echocardiogram (EchoCG) parameters – after myocardial revascularization and stress echocardiography with dobutamine – after stabilization of the state on the 8-10th day. In the Corvitin group, stress echocardiography revealed a greater percentage of viable myocardium (at low doses of dobutamine, the ejection fraction significantly increased in all departments, and the number of akinetic segments at high doses of dobutamine was less than in the control group). The indisputable advantage of such works is that they present real schemes for the use of Corvitin, which can be useful to specialists, and the clinical significance of the results obtained. In this case, the presence and severity of MS is judged indirectly, proceeding from the clinical picture and not being tied to the pathogenesis of MS itself and the role of the studied drug in it.
The second type of publications is clinical studies, which pay special attention to the effect of Corvitin on the pathogenesis of MS. These include an open randomized study involving about 200 patients with ACS with ST segment elevation (Moibenko A.A., Parkhomenko A.N., 2015), in which the authors studied the effectiveness of early prescription of Corvitin as a cardioprotector, adding it to the patient’s treatment regimen. with OKS. In addition to the standard examination, the authors assessed the effect of the drug on the state of the NO-system and LPO. Corvitin reduced the mass of necrotic myocardial damage (calculated from changes in the activity of MB-CPK in the blood serum) by 26.4% (p <0.001), reduced the risk of arrhythmias, which correlated with a decrease in the level of diene conjugates (primary products of lipid peroxidation), stabilization of the leukotriene level C4.In this case, the effect of the drug appeared already from the 2nd hour of administration and reached a maximum by the 5th day.
The third type of publications on the role of quercetin in the prevention of MS is studies that are carried out on models of ischemia-reperfusion, their purpose is to identify the possible effect of the drug on certain pathophysiological links of MS. These are, as a rule, foreign publications. Among them, of particular interest are works devoted to the use of Corvitin for postconditioning (adaptation of the myocardium to reperfusion injury). The induction of short episodes of ischemia during reperfusion triggers a complex biochemical cascade leading to increased tissue resistance to ischemia. The use of pharmacological agents that activate the aforementioned signaling pathways and weaken the severity of reperfusion injury (the so-called pharmacological postconditioning) is safer in relation to ischemic tissue.This ability is possessed by bradykinin, adenosine, opioids, erythropoietin, although none of them, except for adenosine, is widely used in clinical practice due to a number of side effects. A search is underway for safe drugs that potentially have postconditioning effects. Now in the foreign literature there are works using ischemia-reperfusion models devoted to the effect of quercetin on various pathophysiological links of tissue damage and the possibility of its application to increase tissue resistance to ischemia (Bartekova M. et al., 2010, 2012; Jin HB, 2012). In particular, much attention has been paid to the ability of quercetin to inhibit apoptosis of cardiomyocytes. Y. Wang et al (2013), in their ischemia-reperfusion model, investigated quercetin as a drug for pharmacological postconditioning. At the same time it was proved thatthat quercetin affects the signaling pathways of apoptosis, in particular, it activates the PI3K / Akt signaling pathway, increases the expression of Bcl-2 and decreases the expression of Bax, thereby slowing down apoptosis. It is through these mechanisms, according to the authors, that the drug realizes its ability to increase the resistance of ischemic tissue to further reperfusion damage.
The results obtained by foreign authors invariably indicate that the use of quercetin can bring additional advantages to the therapy regimen in terms of MS prevention. But are these properties the basis for the protection of viable cells in the reperfusion zone, or is it just an additional bonus to the well-studied angioprotective properties of quercetin? Further research will help answer these questions, since, as practice shows, the potential of the drug has not been exhausted. Knowledge of the exact mechanisms of realization of the effect of quercetin will help determine the niche of its water-soluble form of Corvitin in the treatment and prevention of reperfusion injuries. On the other hand, the results of domestic research will help in the development of optimal dosage regimens for Corvitin in cardiology, neurology, vascular surgery and other branches of medicine.where clinicians are faced with the need for MS prevention.

Reviews

There are no reviews yet.

Be the first to review “CORVITIN® – the only quercetin injectable (senolytic therapy, cardioprotection, fat metabolism) Covid defence”

You may also like…

SuperhumanStore - longevity, dutasteride mesotherapy, NAD+, peptides, Cerebrolysin, exosomes, anti-aging, senolytics
X
0
    0
    Your Cart
    Your cart is emptyReturn to Shop